SciBX
Science-Business eXchange

THE DISTILLERY

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	Lysine-specific demethylase 2B (KDM2B; JHDM1B)	*In vitro* and mouse studies suggest inhibiting KDM2B could help treat breast cancer. In multiple breast cancer cell lines, shRNA against *KDM2B* decreased proliferation compared with control shRNA. In a mouse model of breast cancer, shRNA against *KDM2B* delayed tumor growth and decreased expression of stem cell markers. Next steps could include developing a KDM2B inhibitor. *SciBX* 7(26); doi:10.1038/scibx.2014.759 Published online July 10, 2014	Unpatented; licensing status not applicable	Kottakis, F. *et al. Cancer Res.*; published online May 22, 2014; doi:10.1158/0008-5472.CAN-13-2733 **Contact:** Philip N. Tsichlis, Tufts Medical Center, Boston, Mass. e-mail: ptsichlis@tuftsmedicalcenter.org